MedTrace Logo

AZD9056 Relative Bioavailability Study

NCT00908934 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-07-23

No results posted yet for this study

Summary

The aims of this study are to compare the blood levels achieved with a new formulation of AZD9056 to an existing formulation of AZD9056 used in previous studies.

Conditions

  • Healthy

Interventions

DRUG

AZD9056 formulation Phase III 50 mg (T)

Given as 50 mg tablet (T)

DRUG

AZD9056 formulation Phase IIb 50 mg (R)

Given as 50 mg tablet (R)

DRUG

AZD9056 formulation Phase III 200 mg (T)

Given as 400 mg (2 x 200 mg tablet (T))

DRUG

AZD9056 formulation Phase IIb 200mg (R)

Given as 400 mg (2 x 200 mg tablet (R))

Sponsors & Collaborators

Principal Investigators

  • Mark Layton · AstraZeneca R&D, Alderley Park, UK

  • Simon Constable · ICON Development Solutions, Manchester, UK

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-05-31
Completion
2009-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00908934 on ClinicalTrials.gov